Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A

New England Journal of Medicine

Volumn 342, Issue 6, 2000, Pages 390-397

  Kyne, Lorraine ^a   Warny, Michel ^a   Qamar, Amir ^a   Kelly, Ciarán P ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CLOSTRIDIUM TOXIN; IMMUNOGLOBULIN G; TOXIN ANTIBODY;

ADULT; AGED; ANTIBIOTIC THERAPY; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL IMMUNITY; BACTERIAL INFECTION; BACTERIUM CARRIER; CLINICAL FEATURE; CLOSTRIDIUM DIFFICILE; CONTROLLED STUDY; FEMALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTIBODIES, BACTERIAL; BACTERIAL PROTEINS; BACTERIAL TOXINS; CLOSTRIDIUM DIFFICILE; COLONY COUNT, MICROBIAL; CROSS INFECTION; DIARRHEA; ENTEROTOXINS; FEMALE; HUMANS; IMMUNOGLOBULIN G; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PROSPECTIVE STUDIES;

EID: 0034628426     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200002103420604     Document Type: Article

References (40)

1. Kelly CP, Pothoulakis C, LaMont JT. Clostridium difficile colitis. N Engl J Med 1994;330:257-62.
2. Kyne L, Moran A, Keane C, O'Neill D. Hospital-acquired diarrhoea in elderly patients: epidemiology and staff awareness. Age Ageing 1998;27: 339-43.
3. Guerrant RL, Hughes JM, Lima NL, Crane J. Diarrhea in developed and developing countries: magnitude, special settings, and etiologies. Rev Infect Dis 1990;12:Suppl 1:S41-S50.
4. McFarland LV. Epidemiology of infectious and iatrogenic nosocomial diarrhea in a cohort of general medicine patients. Am J Infect Control 1995;23:295-305.
5. McFarland LV, Mulligan ME, Kwok RYY, Stamm WE. Nosocomial acquisition of Clostridium difficile infection. N Engl J Med 1989;320:204-10.
6. Pothoulakis C. Pathogenesis of Clestridium difficile-associated diarrhoea. Eur J Gastroenterol Hepatol 1996;8:1041-7.
7. Riegler M, Sedivy R, Pothoulakis C, et al. Clostridium difficile toxin B is more potent than toxin A in damaging human colonic epithelium in vitro. J Clin Invest 1995;95:2004-11.
8. Rubin MS, Bodenstein LE, Kent KC. Severe Clostridium difficile colitis. Dis Colon Rectum 1995;38:350-4.
9. Kyne L, Merry C, O'Connell B, Keane C, O'Neill D. Factors associated with prolonged symptoms and severe disease due to Clostridium difficile. Age Ageing 1999;28:107-13.
10. McFarland LV, Elmer GW, Stamm WE, Mulligan ME. Correlation of immunoblot type, enterotoxin production, and cytotoxin production with clinical manifestations of Clastridium difficile infection in a cohort of hospitalized patients. Infect Immun 1991;59:2456-62.
11. Cheng SH, Lu JJ, Young TG, Perng CL, Chi WM. Clostridium difficile-associated diseases: comparison of symptomatic infection versus carriage on the basis of risk factors, toxin production, and genotyping results. Clin Infect Dis 1997;25:157-8.
12. Viscidi R, Laughon BE, Yolken R, et al. Serum antibody response to toxins A and B of Clostridium difficile. J Infect Dis 1983;148:93-100.
13. Kelly CP, Pothoulakis C, Orellana J, LaMont JT. Human colonic aspirates containing immunoglobulin A antibody to Clostridium difficile toxin A inhibit toxin A-receptor binding. Gastroenterology 1992;102:35-40.
14. Bacon AE III, Fekety R. Immunoglobulin G directed against toxins A and B of Clostridium difficile in the general population and patients with antibiotic-associated diarrhea. Diagn Microbiol Infect Dis 1994;18: 205-9.
15. Johnson S, Gerding DN, Janoff EN. Systemic and mucosal antibody responses to toxin A in patients infected with Clostridium difficile. J Infect Dis 1992;166:1287-94.
16. Kelly CP. Immune response to Clostridium difficile infection. Eur J Gastroenterol Hepatol 1996;8:1048-53.
17. Leung DY, Kelly CP, Boguniewicz M, Pothoulakis C, LaMont JT, Flores A. Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin. J Pediatr 1991;118:633-7.
18. Mulligan ME, Miller SD, McFarland LV, Fung HC, Kwok RY. Elevated levels of serum immunoglobulins in asymptomatic carriers of Clostridium difficile. Clin Infect Dis 1993;16:Suppl 4:S239-S244.
19. Warny M, Vaerman JP, Avesani V, Delmee M. Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection. Infect Immun 1994;62.384-9.
20. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83.
21. McFarland LV, Surawicz CM, Stamm WE. Risk factors for Clastridium difficile carriage and C. difficile-associated diarrhea in a cohort of hospitalized patients. J Infect Dis 1990;162:678-84.
22. Horn SD, Sharkey PD, Bertram DA. Measuring severity of illness: homogeneous case mix groups. Med Care 1983;21:14-30.
23. Charlson ME, Sax FL, MacKenzie CR, Fields SD, Braham RL, Douglas RG Jr. Assessing illness severity: does clinical judgment work? J Chronic Dis 1986;39:439-52.
24. McFarland LV, Coyle MB, Kremer WH, Stamm WE. Rectal swab cultures for Clostridium difficile surveillance studies. J Clin Microbiol 1987; 25:2241-2.
25. Hanff PA, Zaleznik DF, Kent KC, et al. Use of heat shock for culturing Clostridium difficile from rectal swabs. Clin Infect Dis 1993;16:Suppl 4:S245-S247.
26. George WL, Sutter VL, Citron D, Finegold SM. Selective and differential medium for isolation of Clostridium difficile. J Clin Microbiol 1979; 9:214-9.
27. Kelly CP, Pothoulakis C, Vavva F, et al. Anti-Clostridium difficile bovine immunoglobulin concentrate inhibits cytotoxicity and enterotoxicity of C. difficile toxins. Antimicrob Agents Chemother 1996;40:373-9.
28. Hohmann A, LaBrooy J, Davidson GP, Shearman DJ. Measurement of specific antibodies in human intestinal aspirate: effect of the protease inhibitor phenylmethylsulphonyl fluoride. J Immunol Methods 1983;64: 199-204.
29. Sullivan NM, Pellet S, Wilkins TD. Purification and characterization of toxins A and B of Clostridium difficile. Infect Immun 1982;35:1032-40.
30. von Eichel-Streiber C, Harperath U, Bosse D, Hadding U. Purification of two high molecular weight toxins of Clostridium difficile which are antigenically related. Microb Pathog 1987;2:307-18.
31. Shim JK, Johnson S, Samore MH, Bliss DZ, Gerding DN. Primary symptomless colonisation by Clostridium difficile and decreased risk of subsequent diarrhoea. Lancet 1998;351:633-6.
32. Starr JM, Rogers TR, Impallomeni M. Hospital-acquired C. difficile diarrhoea and herd immunity. Lancet 1997;349:426-8.
33. Gerding DN, Johnson S, Peterson LR, Mulligan ME, Silva J Jr. Clostridium difficile-associated diarrhea and colitis. Infect Control Hosp Epidemiol 1995;16:459-77.
34. Kent KC, Rubin MS, Wroblewski L, Hanff PA, Silen W. The impact of Clostridium difficile on a surgical service: a prospective study of 374 patients. Ann Surg 1998;227:296-301.
35. Johnson S, Clabots CR, Linn FV, Olson MM, Peterson LR, Gerding DN. Nosocomial Clostridium difficile colonisation and disease. Lancet 1990;336:97-100.
36. Clabots CR, Johnson S, Olson MM, Peterson LR, Gcrding DN. Acquisition of Clostridium difficile by hospitalized patients: evidence for colonized new admissions as a source of infection. I Infect Dis 1992;166:561-7.
37. Samore MH, DeGirolami PC, Tlucko A, Lichtenberg DA, Melvin ZA, Karchmer AW. Clostridium difficile colonization and diarrhea at a tertiary care hospital. Clin Infect Dis 1994;18:181-7.
38. Bliss DZ, Johnson S, Savik K, Clabots CR, Willard K, Gerding DN. Acquisition of Clostridium difficile and Clostridium difficile-associated diarrhea in hospitalized patients receiving tube feeding. Ann Intern Med 1998;129:1012-9.
39. Kyne L, Kelly CP. Prospect for a vaccine for Clostridium difficile. BioDrugs 1998;10:173-81.
40. Salcedo J, Keates S, Pothoulakis C, et al. Intravenous immunoglobulin therapy for severe Clostridium difficile colitis. Gut 1997;41:366-70.